- Home
- CANG vs SVRA Comparison
CANG vs SVRA Comparison
Compare CANG & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANG
- SVRA
- Stock Information
- Founded
- CANG 2010
- SVRA 2007
- Country
- CANG China
- SVRA United States
- Employees
- CANG N/A
- SVRA N/A
- Industry
- CANG Computer Software: Prepackaged Software
- SVRA Biotechnology: Pharmaceutical Preparations
- Sector
- CANG Technology
- SVRA Health Care
- Exchange
- CANG Nasdaq
- SVRA Nasdaq
- Market Cap
- CANG 544.1M
- SVRA 433.8M
- IPO Year
- CANG 2018
- SVRA N/A
- Fundamental
- Price
- CANG $4.77
- SVRA $2.56
- Analyst Decision
- CANG Strong Buy
- SVRA Buy
- Analyst Count
- CANG 1
- SVRA 5
- Target Price
- CANG $8.00
- SVRA $5.60
- AVG Volume (30 Days)
- CANG 845.2K
- SVRA 1.0M
- Earning Date
- CANG 08-28-2025
- SVRA 08-11-2025
- Dividend Yield
- CANG N/A
- SVRA N/A
- EPS Growth
- CANG N/A
- SVRA N/A
- EPS
- CANG 0.00
- SVRA N/A
- Revenue
- CANG $247,219,627.00
- SVRA N/A
- Revenue This Year
- CANG $431.64
- SVRA N/A
- Revenue Next Year
- CANG $23.36
- SVRA N/A
- P/E Ratio
- CANG $2,510.32
- SVRA N/A
- Revenue Growth
- CANG 46.60
- SVRA N/A
- 52 Week Low
- CANG $1.40
- SVRA $1.89
- 52 Week High
- CANG $9.66
- SVRA $4.74
- Technical
- Relative Strength Index (RSI)
- CANG 44.06
- SVRA 57.01
- Support Level
- CANG $4.90
- SVRA $2.25
- Resistance Level
- CANG $5.14
- SVRA $2.84
- Average True Range (ATR)
- CANG 0.29
- SVRA 0.15
- MACD
- CANG -0.07
- SVRA 0.04
- Stochastic Oscillator
- CANG 3.92
- SVRA 53.33
About CANG Cango Inc. each representing two (2)
Cango Inc through its subsidiaries, variable interest entities (VIEs), and subsidiaries of the VIEs, are principally engaged in bitcoin mining business, and the automobile trading transaction, automotive financing facilitation, and aftermarket service facilitation businesses (collectively, the automobile and related businesses). The Company conducts the bitcoin mining business mainly through its subsidiaries, and the automobile and related businesses are conducted through the Company's VIEs and the subsidiaries of the VIEs. The company derives majority of its revenue from the bitcoin mining business.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.